<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34880495</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>601</Volume><Issue>7891</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structure of pathological TDP-43 filaments from ALS with FTLD.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>143</EndPage><MedlinePgn>139-143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-04199-3</ELocationID><Abstract><AbstractText>The abnormal aggregation of TAR DNA-binding protein 43&#x2009;kDa (TDP-43) in neurons and glia is the defining pathological hallmark of the&#xa0;neurodegenerative disease amyotrophic lateral sclerosis (ALS) and multiple forms of frontotemporal lobar degeneration (FTLD)<sup>1,2</sup>. It is also common in other diseases, including Alzheimer's and Parkinson's. No disease-modifying therapies exist for these conditions and early diagnosis is not possible. The structures of pathological TDP-43 aggregates are unknown. Here we used cryo-electron microscopy to determine the structures of aggregated TDP-43 in the frontal and motor cortices of an individual who had ALS with FTLD and from the frontal cortex of a second individual with the same diagnosis. An identical amyloid-like filament structure comprising a single protofilament was found in both brain regions and individuals. The ordered filament core spans residues 282-360 in the TDP-43 low-complexity domain and adopts a previously undescribed double-spiral-shaped fold, which shows no similarity to those of TDP-43 filaments formed in vitro<sup>3,4</sup>. An abundance of glycine and neutral polar residues facilitates numerous turns and restricts &#x3b2;-strand length, which results in an absence of &#x3b2;-sheet stacking that is associated with cross-&#x3b2; amyloid structure. An uneven distribution of residues gives rise to structurally and chemically distinct surfaces that face external densities and suggest possible ligand-binding sites. This work enhances our understanding of the molecular pathogenesis of ALS and FTLD and informs the development of diagnostic and therapeutic agents that target aggregated TDP-43.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arseni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7585-288X</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kametani</LastName><ForeName>Fuyuki</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9125-7001</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3400-9815</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioural Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryskeldi-Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8176-2618</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. bfalcon@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/25</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Jan;601(7891):29-30</RefSource><PMID Version="1">34880481</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests</b>
. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34880495</ArticleId><ArticleId IdType="mid">EMS140820</ArticleId><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-04199-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nature Struct Mol Biol. 2019;26:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK. Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nature Commun. 2021;12:1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains. Cell Rep. 2013;4:124&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 Mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nature Commun. 2017;8:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W-L, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;116:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135:3380&#x2013;3391.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L-L, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288:19614&#x2013;19624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Binda C, et al. Cross-talk and ammonia channeling between active centers in the unexpected domain arrangement of glutamate synthase. Structure. 2000;8:1299&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11188694</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson GN, Cuenca F, Neidle S. Topology conservation and loop flexibility in quadruplex&#x2212;drug recognition: crystal structures of inter- and intramolecular telomeric DNA quadruplex&#x2212;drug complexes. J Mol Biol. 2008;381:1145&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">18619463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021 doi: 10.1038/s41586-021-03911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03911-7</ArticleId><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature. 2020;585:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nature Commun. 2019;10:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs MRH, et al. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol. 2005;149:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease with PET ligand APN-1607. Acta Neuropathol. 2021;141:697&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043864</ArticleId><ArticleId IdType="pubmed">33723967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 2013;125:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593646</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013;125:121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. Physiologically important electrolytes as regulators of TDP-43 aggregation and droplet-phase behavior. Biochemistry. 2019;58:590&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">30489059</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife. 2019;8:e43584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017;171:615&#x2013;627.:e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. CryoEM structure of the low-complexity domain of hnRNPA2 and its conversion to pathogenic amyloid. Nature Commun. 2020;11:4090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427792</ArticleId><ArticleId IdType="pubmed">32796831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. The nuclear localization sequence mediates hnRNPA1 amyloid fibril formation revealed by cryoEM structure. Nature Commun. 2020;11:6349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733464</ArticleId><ArticleId IdType="pubmed">33311513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Ghosh U, Thurber KR, Kato M, Tycko R. Molecular structure and interactions within amyloid-like fibrils formed by a low-complexity protein sequence from FUS. Nature Commun. 2020;11:5735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665218</ArticleId><ArticleId IdType="pubmed">33184287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK-H, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132:1186&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nature Struct Mol Biol. 2011;18:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting diseaseprogression rates. Nature Neurosci. 2019;22:65.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nature Commun. 2018;9:4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Amyotrophic lateral sclerosis with dementia: The clinicopathological spectrum. Neuropathology. 2004;24:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068178</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, et al. Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochem Biophys Res Commun. 2012;417:116&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22133678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Hasegawa M. In: Experimental Models of Parkinson&#x2019;s Disease. Imai Y, editor. Springer; US: 2021. Electron microscopic analysis of &#x3b1;-synuclein fibrils; pp. 17&#x2013;25.</Citation></Reference><Reference><Citation>Kametani F, et al. Comparison of common and disease-specific post-translational modifications of pathological tau associated with a wide range of tauopathies. Front Neurosci. 2020;14:581936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672045</ArticleId><ArticleId IdType="pubmed">33250706</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2019;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr Sect Struct Biol. 2020;76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryo-microscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, Lohkamp B, Emsley P. Current developments in Coot for macromolecular model building of electron cryo-microscopy and erystallographic data. Protein Sci. 2020;29:1055&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr Sect Struct Biol. 2018;74:519&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096486</ArticleId><ArticleId IdType="pubmed">29872003</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr D Biol Crystallogr. 2015;71:136&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304694</ArticleId><ArticleId IdType="pubmed">25615868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Palmer CM, Burnley T, Murshudov GN. Cryo-EM single particle structure refinement and map calculation using Servalcat. bioRxiv. 2021:2021.05.04.442493. doi: 10.1101/2021.05.04.442493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.04.442493</ArticleId><ArticleId IdType="pmc">PMC8489229</ArticleId><ArticleId IdType="pubmed">34605431</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>